Company
Eurofarma
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
6
5 still marketed
Novel approvals
2
Approvals since 2021
0
Originals and new uses
Phase 3 trials
53
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
- Phase 353
Recent approvals
Originals and efficacy supplements, newest first.
No approvals since 2000.
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne VulgarisPivotal-lookingRecruiting
Eurofarma Laboratorios S.A.Industry
NCT06905210 · 531 participants (planned) · Start Aug 24, 2026 · Primary completion Feb 2027
Drug: Experimental drug (Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg); Placebo · For: Acne Vulgaris; Acne Vulgaris on the Face
Sites: Salvador, Brazil; Brasília, Brazil; Goiânia, Brazil · 18 sites in all
Marketed drugs (5)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.